DEFA14A: Endo, Inc. Issues Supplemental Disclosures Amid Shareholder Lawsuits Challenging Mallinckrodt Merger

Endo, Inc. has filed supplemental disclosures to its definitive proxy statement in response to shareholder complaints and demand letters challenging its proposed merger with Mallinckrodt plc, aiming to moot claims and avoid transaction delays.

Summary

• Endo, Inc. (Endo) entered into a Transaction Agreement with Mallinckrodt plc (Mallinckrodt) and Merger Sub LLC on March 13, 2025, for Merger Sub to merge into Endo, making Endo a wholly-owned subsidiary of Mallinckrodt.
• As of June 5, 2025, three complaints have been filed in the Supreme Court of the State of New York by purported shareholders against Endo and its board, alleging negligent misrepresentation, concealment, and negligence related to the Transaction.
• Additionally, 11 demand letters from purported shareholders allege similar deficiencies, securities law violations, and breaches of fiduciary duties.
• Endo believes these claims are without merit and that no further disclosure is legally required, but is making supplemental disclosures to moot plaintiffs' claims, avoid transaction delays, and minimize litigation costs.
• These supplemental disclosures amend and supplement the Definitive Proxy Statement filed on May 12, 2025, including details about confidentiality agreements not containing standstill provisions.
• Financial advisor opinions (Goldman Sachs) are supplemented with specific figures: Endo Stand-Alone terminal year unlevered free cash flow of $325 million, net debt of $2.03 billion as of December 31, 2024, and 77.5 million fully diluted outstanding shares.
• Pro Forma Combined Company terminal year unlevered free cash flow of $654 million, net debt of $2.828 billion as of December 31, 2024, and 40.8 million fully diluted outstanding shares of post-completion Mallinckrodt shares.
• Projected net debt for Endo Stand-Alone for fiscal years 2025-2028 ranges from $1.854 billion to $797 million, and for Pro Forma Combined Company from $2.782 billion to $0.168 billion (inclusive of Acthar settlement payments).
• Selected Transactions Analysis applied EV/LTM adjusted EBITDA multiples of 6.2x to 8.7x to Endo's LTM adjusted EBITDA of $624 million as of December 31, 2024.
• Endo's 280G Mitigation Actions clarify that they do not include gross-up payments or reimbursement of excise taxes for executives.
• The supplemental disclosures do not affect the timing of the Endo Special Meeting, scheduled for June 13, 2025, or the board's recommendation that shareholders vote in favor of the Transaction.

Sentiment

Score: 5

Explanation: The document addresses legal challenges to a major merger, which introduces uncertainty and potential costs (negative). However, the company is proactively addressing these by providing supplemental disclosures and maintains its belief that claims are without merit and the merger timing is unaffected (positive/neutral). The overall sentiment is neutral as it's a procedural update to mitigate risks rather than a performance announcement.

Positives

• Endo management believes the shareholder claims are without merit, indicating confidence in their position.
• The company is proactively making supplemental disclosures to moot claims and minimize litigation costs, demonstrating an effort to mitigate risks and avoid transaction delays.
• The board of directors' recommendation for the Transaction remains unchanged, signaling continued commitment to the merger.

Negatives

• Three shareholder complaints and 11 demand letters have been filed/sent, alleging serious issues such as negligent misrepresentation, concealment, negligence, securities law violations, and breaches of fiduciary duties.
• There is a potential for additional similar complaints to be filed, existing matters to be amended, or more demand letters to be received by the company, indicating ongoing legal uncertainty.

Risks

• Transaction-related risks include the parties' ability to successfully integrate Mallinckrodt's and Endo's businesses, unanticipated integration costs, and uncertainties related to a future separation of the combined generics pharmaceuticals and sterile injectables businesses.
• Risks that the expected benefits and synergies of the proposed transactions may not be fully realized in a timely manner, or at all.
• Uncertainty regarding the timing of the closing of the proposed business combination transaction, and the risk that conditions to the transaction may not be satisfied or waived.
• Potential for any regulatory approval, consent, or authorization required for the proposed transaction not to be obtained or to be obtained subject to unanticipated conditions.
• The effect of the announcement, pendency, or completion of the proposed transactions on the parties' business relationships, operations, and the long-term value of their shares.
• Risks that the proposed transactions may disrupt current plans and operations, and potential difficulties in hiring, retaining, and motivating employees.
• Mallinckrodt's increased indebtedness as a result of the proposed business combination transaction and significant transaction costs.
• Potential litigation relating to the proposed transactions that could be instituted against Mallinckrodt, Endo, or their respective officers or directors.
• Risks related to Mallinckrodt's business, including governmental investigations, regulatory actions, lawsuits, compliance obligations, and scrutiny related to sales, marketing, and pricing practices.
• Pricing pressure on certain products due to legal changes or changes in insurers' reimbursement practices, and the reimbursement practices of governmental health administration authorities.
• Risks related to Mallinckrodt's ability to successfully develop, commercialize, or launch new products, protect intellectual property rights, and manage complex manufacturing processes.
• Risks related to Endo's business, including future capital expenditures, changes in competitive, market, or regulatory conditions, and the impacts of competition such as those related to XIAFLEX.
• The timing and uncertainty of the results of both the research and development and regulatory processes, and the impacts of healthcare and cost containment reforms.
• Litigation risks, issues associated with Endo's supply chain, and the effectiveness of advertising and promotional campaigns.

Future Outlook

The document primarily focuses on current legal challenges and supplemental disclosures related to a pending merger. It reiterates the intent to combine generics and sterile injectables businesses and potentially separate them later. It also outlines various risks that could cause actual events to differ materially from forward-looking statements, emphasizing uncertainties related to integration, realization of synergies, regulatory approvals, and market conditions, without providing specific new guidance on future financial performance.

Management Comments

• "The Company believes that the claims asserted in the Matters are without merit, and that no further disclosure is required under applicable law."
• "Nonetheless, to specifically moot plaintiffs claims, to avoid the risk that the Matters may delay or otherwise adversely affect the Transaction and to minimize the costs, risks and uncertainties inherent in litigation, the Company is making supplemental disclosures."
• "Nothing in this Schedule 14A shall be deemed an admission of the legal necessity or materiality under applicable laws of any of the Supplemental Disclosures."
• "The Supplemental Disclosures contained herein do not affect the timing of the special meeting of the stockholders of Endo (the Endo Special Meeting), which is scheduled to be held on June 13, 2025, or the Company board of directors recommendation that the shareholders of the Company vote in favor of the Transaction and related proposals."

Industry Context

This filing is specific to a merger within the specialty pharmaceutical industry. The references to 'selected transactions in the specialty pharmaceutical industry since 2010' for financial analysis indicate that the merger is part of ongoing consolidation or strategic realignments within this sector. The risks section also highlights industry-wide challenges such as pricing pressure, reimbursement practices, and regulatory scrutiny, which are common in the pharmaceutical sector.

Comparison to Industry Standards

• The document references an applied range of EV/LTM adjusted EBITDA multiples of 6.2x to 8.7x based on selected transactions in the specialty pharmaceutical industry since 2010. However, specific comparable companies, projects, or their individual results are not detailed within this filing.

Corporate Governance

Legal Proceedings

• Three complaints have been filed in the Supreme Court of the State of New York (one in Chemung County and two in New York County) by purported shareholders against Endo and members of its board of directors in connection with the Transaction.
• These complaints include allegations of negligent misrepresentation, concealment, and negligence.
• Additionally, 11 demand letters have been sent by purported shareholders alleging similar deficiencies, violations of securities law, and, in at least one instance, breaches of fiduciary duties.
• The Company believes that the claims asserted in these matters are without merit.
• It is possible that additional, similar complaints may be filed, that the described matters may be amended, or that additional demand letters will be received by the Company.

Stakeholder Impact

• **Shareholders**: Purported shareholders have initiated legal challenges (complaints and demand letters), indicating potential dissatisfaction or concerns regarding the merger disclosures. The supplemental disclosures are intended to address these concerns and facilitate the merger vote.
• **Management/Executives**: The clarification regarding 280G mitigation actions impacts executive compensation related to the merger, specifically excluding gross-up payments for excise taxes.
• **Employees**: The proposed transactions carry risks of disrupting current plans and operations, and potential difficulties in hiring, retaining, and motivating employees.
• **Customers/Suppliers**: The announcement, pendency, or completion of the proposed transactions could affect existing business relationships and operations generally, and the ability to maintain relationships with suppliers and customers.
• **Creditors**: Mallinckrodt's increased indebtedness and its ability to access debt markets are noted risks, which could impact creditors' assessment of the combined entity's financial health and repayment capacity.

Next Steps

• The Endo Special Meeting is scheduled for June 13, 2025, for stockholders to vote on the Transaction and related proposals.
• Mallinckrodt and Endo may file other relevant documents with the SEC regarding the proposed transaction.
• There is a possibility that additional similar complaints may be filed, that the current matters may be amended, or that additional demand letters will be received by the Company.
• A future separation of the combined generics pharmaceuticals businesses of Mallinckrodt and Endo and Endo's sterile injectables business is anticipated at a later date.

Key Dates

Recommendation

Keywords

SEC Filing, Proxy Statement, Merger, Acquisition, Shareholder Lawsuit, Litigation, Supplemental Disclosure, Endo Inc., Mallinckrodt plc, Pharmaceuticals, Corporate Governance, Financial Advisory, Discounted Cash Flow, EBITDA, Net Debt, Acthar Gel, XIAFLEX, Specialty Pharmaceutical